First author
|
Oxford score (6) random blinding follow-up
|
Procedure
|
Comparison (number of analyzed patients)
|
Drug dosing schedule
|
Duration of treatment
|
Preoperative
|
Intraoperative
|
Postoperative
|
| Bayliff (26) |
2 /2/1 |
Thoracic |
1. Propranolol (49) |
10 mg PO |
|
40 mg/d PO |
5 days |
|
|
|
2. Placebo (50) |
|
|
|
|
| Caramella (27) |
1 /2/1 |
Vascular; other |
1. Diltiazem (32) |
0.15 mg/kg IV |
|
5 µg · kg-1 · min-1 IV |
3–13 h |
|
|
|
2. Placebo (34) |
|
|
|
|
| Coleman (28) |
1 /0/0 |
Major noncardiac |
1. + 2. Metoprolol (24) |
Group 1: 2 mg IV |
|
|
PM |
|
|
|
3. Placebo (14) |
Group 2: 4 mg IV |
|
|
|
| Davies (29) |
2 /1/0 |
Vascular |
1. Atenolol (20) |
50 mg PO |
|
|
PM |
|
|
|
2. Placebo (20) |
|
|
|
|
| Dodds (30) |
1 /0/1 |
Vascular; other |
1. Nitroglycerin (22) |
0.3–0.9 µg · kg-1 · min-1 IV |
30 min |
|
|
|
2. No drug (23) |
|
|
|
|
| Ellis (31) |
2 /2/0 |
Major noncardiac |
1. Clonidine (30) |
0.2 mg transdermal and 0.3 mg PO
|
unquantified transdermal release |
3 d |
|
|
|
2. Placebo (31) |
|
|
|
| Ghignone (32) |
2 /0/0 |
Orthopedic; abdominal; ENT |
1. Clonidine (15) |
5 µg/kg IV |
|
|
PM |
|
|
|
2. No drug (15) |
|
|
|
|
| Godet (33) |
1 /1/0 |
Vascular |
1. Diltiazem (15) |
0.15 mg/kg IV |
|
5 µg · kg-1 · min-1 IV |
2 h |
|
|
|
2. Placebo (15) |
|
|
|
|
| Jakobsen (25) |
1 /2/1 |
Thoracic |
1. Metoprolol (15) |
100 mg PO |
|
100 mg/d PO |
4–10 d |
|
|
|
2. Placebo (15) |
|
|
|
|
| Lindgren (34) |
1 /1/0 |
Thoracic |
1. Verapamil (12) |
|
|
10 µg · kg-1 · h-1 IV from end of surgery to day 1 then 240 mg/d PO
|
7 d |
|
|
|
2. Placebo (13) |
|
|
|
| Magnusson (35) |
1 /0/1 |
Abdominal |
1. Metoprolol (13) |
200 mg/d PO for 14–34 days
|
|
|
14–34 d preop + PM
|
|
|
|
2. No drug (14) |
|
|
|
|
|
|
15 mg IV before surgery |
|
|
|
| McSPI (36) |
2 /1/1 |
Vascular |
1. + 2. Mivazerol (197) |
Group 1: 2 µg/kg IV |
|
Group 1: 0.75 µg · kg-1 · h-1 IV
|
3 d |
|
|
|
3. Placebo (103) |
Group 2: 4 µg/kg IV |
|
|
|
|
|
|
|
|
Group 2: 1.5 µg · kg-1 · h-1 IV |
|
| Oliver (37) |
2 /1/0 |
Vascular; thoracic; abdominal; orthopedic
|
1. Mivazerol (956) |
4 µg/kg IV |
|
1.5 µg · kg-1 · h-1 IV |
3 d |
|
|
2. Placebo (941) |
|
|
|
|
| Pluskwa (38) |
2 /2/1 |
Vascular |
1. Clonidine (14) |
0.3 mg PO |
|
|
PM |
|
|
|
2. Placebo (15) |
|
|
|
|
| Poldermans (22) |
2 /0/1 |
Vascular |
1. Bisoprolol (59) |
5–10 mg PO for 37 days
|
|
5–10 mg/d PO or metoprolol IV
|
30 d |
|
|
|
2. No drug (53) |
|
|
| Raby (39) |
2 /1/0 |
Vascular |
1. Esmolol (15) |
|
|
100–300 µg · kg-1 · min-1
|
2 d |
|
|
|
2. Placebo (11) |
|
|
|
| Stone (20) |
1 /0/0 |
Abdominal; orthopedic; vascular
|
1. Labetalol (29) |
Group 1: Labetalol 100 mg PO
|
|
|
PM |
|
|
2. Atenolol (30) |
|
|
|
|
|
|
3. Oxprenolol (30) |
Group 2: Atenolol 50 mg PO
|
|
|
|
|
|
|
4. No drug (39) |
|
|
|
|
|
|
|
Group 3: Oxprenolol 20 mg |
|
|
|
| Stühmeier (40) |
2 /2/1 |
Vascular |
1. Clonidine (145) |
2 µg/kg PO |
|
|
PM |
|
|
|
2. Placebo (152) |
|
|
|
|
| Urban (41) |
1 /0/1 |
Total knee arthroplasty |
1. Esmolol/metoprolol (52) |
|
|
Esmolol 250 mg/h IV from end of surgery to day 1 then metoprolol 100–200 mg/d PO
|
2 d |
|
|
|
2. No drug (55) |
|
|
|
| Wallace (23) |
2 /2/1 |
Vascular; abdominal; orthopedic; other
|
1. Atenolol (99) |
5–10 mg IV |
|
10–20 mg/d IV or 50–100 mg/d PO
|
7 d |
|
|
2. Placebo (101) |
|
|
|
| Zaugg (42) |
1 /0/1 |
Abdominal; other |
1. No treatment (19) |
Group 1: |
Group 1: 0 |
Group 1: 0 |
3 d |
|
|
|
2. + 3. Atenolol (40) |
Group 2: 5–10 mg IV |
Group 2: 0 |
Group 2: 10–20 mg IV |
|
|
|
|
|
0 Group 3: 0 |
Group 3: variable |
Group 3: 0 |
|
|
| ENT = ear, nose, throat; PO = orally; PM = premedication. |
